NKTR
Nektar Therapeutics
October 1, 2026 · pre-market
- Rarity
- 4.15
- Peak move
- −23.08%
- Float cap
- $1.2B
Nektar Therapeutics is a clinical-stage, research-based biopharmaceutical company focused on immunotherapy. It discovers and develops immunomodulatory agents that selectively induce, amplify, attenuate or prevent immune responses. Its pipeline targets autoimmune diseases, including atopic dermatitis and alopecia areata, and cancer, advancing drug candidates through preclinical and clinical development.
Where do you see this going?
no votes yetVoting closed at 4:00 PM ET.
What we found
2 events · 1 from SEC or newswire · 1 timed with the move- Timed with the move
clinical_readoutNektar Therapeutics reported new data from its Phase 2b REZOLVE-AA clinical trial in alopecia areata and made available a presentation with additional trial information.
SEC8-K 0001213900-26-105453 clinical_readoutNektar Therapeutics and collaborators presented late-breaking biomarker data at EADV Congress 2026 showing early molecular responses to rezpegaldesleukin as early as Week 2 in atopic dermatitis patients, correlated with subsequent clinical response.